Effects of Atorvastatin and Simvastatin on Low-Density Lipoprotein Subtraction Profile,Low-Density Lipoprotein Oxidizability,and Antibodies to Oxidized Low-Density Lipoprotein in Relation to Carotid Intima Media Thickness in Familial Hypercholesterolemia
Restricted accessResearch articleFirst published online April, 2004
Effects of Atorvastatin and Simvastatin on Low-Density Lipoprotein Subtraction Profile,Low-Density Lipoprotein Oxidizability,and Antibodies to Oxidized Low-Density Lipoprotein in Relation to Carotid Intima Media Thickness in Familial Hypercholesterolemia
Little is known about the effects of statins on the quality of circulating low-density lipoprotein (LDL) in relation to atherosclerosis progression.
Methods
In a double-blind, randomized trial of 325 patients with familial hypercholesterolemia (FH), we assessed the effects of high-dose atorvastatin (80 mg) and conventional-dose simvastatin (40 mg) on LDL subtraction profile (n = 289), LDL oxidizability (n = 121), and circulating autoantibodies to oxidized LDL (n = 220). Progression of atherosclerosis was measured by carotid intima media thickness (IMT) (n = 325).
Results
At baseline, the patients showed an intermediate LDL subtraction profile composed of three LDL subtractions (LDL1, LDL2, LDL3), with LDL2 as the predominant subtraction. A strong negative correlation was found between plasma triglycerides and the LDL subtraction profile (r = - .64, p = .000). Both plasma levels of triglycerides and small dense LDL3 correlated weakly with baseline IMT (r = .11, p = .04 and r = .15, p = .01, respectively; n = 289). No association was found between baseline IMT and oxidation parameters or circulating antibodies to oxidized LDL. Atorvastatin reduced triglycerides, LDL cholesterol, and all LDL subtractions to a greater extent than did simvastatin and led to regression of carotid IMT. However, LDL subtraction pattern and plasma levels of autoantibodies to oxidized LDL remained unchanged in both treatment groups, and LDL oxidizability increased minimally to a similar extent in both groups. Significant treatment differences were found for the rate of in vitro oxidation of LDL and the amount of dienes formed during in vitro oxidation of LDL, which both decreased more following atorvastatin than after simvastatin.
Conclusion
Change of IMT after statin treatment was associated with baseline IMT (r = .41), LDL cholesterol (r = -.20), and the amount of dienes formed during in vitro oxidation of LDL (r = .28) but not with plasma levels of antibodies to oxidized LDL, in vitro LDL oxidizability, and LDL subtraction profile.
SlackJ.Risk of ischemic heart disease in familial hyperlipo-proteinemic states.Lancet1969; ii: 1380–2.
2.
Simon Broome Register Group.Risk of fatal coronary artery disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.BMJ1991; 303: 893–6.
3.
AustinM.A., BreslowJ.L., HennekesC.H.Low density lipoprotein subclass patterns and risk of myocardial infarction.JAMA1988; 260: 1917–21.
4.
SwinkelsD.W., DemackerP.N.M., HendriksJ.C.M., van't LaarA.Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals.Arteriosclerosis1989; 9: 604–13.
5.
CamposH., GenestJ.J.Jr, BlijlevensE.Low density lipoprotein particle size and coronary artery disease.Arterioscl Thromb1992; 12: 187–95.
6.
De GraafJ., DemackerP.N.M., StalenhoefA.F.H.The effect of simvastatin on the low-density lipoprotein subfraction profile and its composition in familial hypercholesterolemia.Neth J Med1993; 43: 254–61.
7.
HoogerbruggeN., JansenH.Atorvastatin increases low-density lipoprotein size and enhances high-density cholesterol concentration in male but not in female patients with familial hypercholesterolemia.Atherosclerosis1999; 146: 167–74.
8.
KraussR.M., BurkeD.J.Identification of multiple subclasses of plasma low-density lipoproteins in normal humans.J Lipid Res1982; 23: 97–104.
9.
SwinkelsD.W., Hak-LemmersH.L.M., DemackerP.N.M.Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions.J Lipid Res1987; 28: 1233–9.
10.
PackardC.J., ShepherdJ.Lipoprotein heterogeneity and apolipoprotein B metabolism.Arterioscl Thromb Vasc Biol1997; 17: 3542–56.
11.
GriffinB.A., CaslakeM.J., YipB.Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation.Atherosclerosis1990; 83: 59–67.
12.
De GraafJ., HendriksJ.C.M., DemackerP.N.M., StalenhoefA.F.H.Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects.Arterioscl Thromb Vasc Biol1991; 11: 298–306.
13.
TribbleD.L., HollL.G., WoodP.D., KraussR.M.Variations in oxidative susceptibility among six low-density lipoprotein subfractions of differing density and particle size.Atheroslcerosis1992; 93: 189–99.
14.
DejagerS., BruckertE., ChapmanM.J.Dense low density lipoprotein subspecies with diminished oxidative resistance predominant in combined hyperlipidemia.J Lipid Res1993; 34: 295–308.
15.
ChaitA., BrazgR.L., TribbleD.L., KraussR.M.Susceptihility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic phenotype, pattern-B.Am J Med1993; 94: 350–6.
16.
SalonenJ.T., Yla HerttualaS., YamamotoR.Autoantibody against oxidized LDL and progression of carotid atherosclerosis.Lancet1992; 339: 883–7.
17.
LehtimakiT., LehtinenS., SolakiviS.Autoantibodies against oxidized low-density lipoprotein in patients with angiographically verified coronary artery disease.Arterioscl Thromb Vasc Biol1999; 19: 23–7.
18.
CamposH., ArnoldsK.S., BalestraM.E.Differences in receptor binding of LDL subfractions.Arterioscler Thromb Vasc Biol1996; 16: 794–801.
19.
De GraafJ., HendriksJ.C.M., SwinkelsD.W.Differences in LDL receptor-mediated metabolism of three low-density lipoprotein subfractions by human monocyte-derived macrophages: impact on the risk for atherosclerosis.Artery1993; 20: 201–30.
20.
DeckelbaumR.J., EisenbergS., OschryY.Reversible modification of human plasma low-density lipoprotiens toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters.J Biol Chem1982; 257: 6509–17.
21.
AustinM.A., KraussR.M.Genetic control of low-density lipoprotein subclasses.Lancet1986; ii: 592–5.
22.
De GraafJ., SwinkelsD.W., de HaanA.F.J.Both inherited susceptibility and environmental exposure determine the low-density lipoprotein subfraction pattern distribution in healthy Dutch families.Am J Hum Genet1992; 51: 1295–310.
23.
BredieS.J.H., KiemeneyL.A., deHaanA.F.J.Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia.Am J Hum Genet1996; 58: 812–22.
24.
SmildeT.J., TripM.D., WollersheimH.Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima-media thickness in patients with familial hypercholesterolemia.Clin Drug Invest2000; 20: 67–79.
25.
SmildeT.J., van WissenH., WollersheimH.Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia: a randomised trial.Lancet2001; 357: 577–81.
26.
DemackerP.N.M., HesselsM., Toenhake-DijkstraH., BaadenhuijsenH.Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample to reagent ratio.Clin Chem1997; 43: 663–8.
27.
StalenhoefA.F.H., de GraafJ., WittekoekM.E.The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low-density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.Atherosclerosis2000; 153: 129–38.
28.
EsterbauerH., StrieglG., PuhlH., RothenederM.Continuous monitoring of in vivo oxidation of human low density lipoprotein.Free Radic Res Commun1989; 6: 67–75.
29.
KleinveldH.A., Hak-LemmersH.L., StalenhoefA.F.H., DemackerP.N.M.Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein.Clin Chem1992; 38: 2066–72.
30.
Van TitsL., de WaartF., Hak-LemmersH.L.Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers.Free Radic Biol Med2001; 30: 1122–9.
31.
SmildeT.J., WollersheimH., Van LangenH., StalenhoefA.F.H.Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness.Clin Sci1997; 93: 317–24.
32.
McNamaraJ.R., JennerJ.L., ZhenglingL.Change in LDL particle size is associated with change in plasma triglyceride concentration.Arterioscler Thromb Vasc Biol1992; 12: 1284–90.
33.
GriffinB.A., FreemanD.J., TaitG.W.Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.Atherosclerosis1994; 106: 241–53.
34.
TanC.E., FosterL., CaslakeM.J.Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women.Arterioscler Thromb Vasc Biol1995; 15: 1839–48.
35.
ZambonA., HokansonJ.E., BrownB.G., BrunzellJ.D.Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.Circulation1999; 99: 1959–64.
36.
Van den AkkerJ.M., BredieS.J.H., DiepenveenS.H.A.Ator-vastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.J Nephrol2003; 16: 238–44.
37.
RaalF.J., AreiasA.J., WaisbergR., von ArbM.Susceptibility of low-density lipoprotein to oxidation in familial hypercholesterolemia.Atherosclerosis1995; 115: 9–15.
38.
RaalF.J., PicherG.J., WaisbergR.Low-density lipoprotein cholesterol bulk is the pivotel determinant of atherosclerosis in familial hypercholesterolemia.Am J Cardiol1999; 83: 1330–33.
39.
KleinveldH.A., DemackerP.N., de HaanA.F., StalenhoefA.F.Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl CoA reductase inhibitors.Eur I Clin Invest1993; 23: 289–95.
40.
OranjeW.A., SelsJ-P.J.E., Rondas-ColbersG.J.W.M.Effect of atorvastatin on LDL oxidation and antioxidants in normo-cholesterolemic type 2 diabetic patients.Clin Chim Acta2001; 311: 91–4.
41.
KontushA., HubnerC., FinckhB.How different constituents of low density lipoprotein determine its oxidizability by copper: a correlational approach.Free Radic Res1996; 24: 135–47.
42.
SalonenJ.T., SalonenR.Ultrasonographically assessed carotid morphology and the risk of coronary heart disease.Arterioscler Thromb1991; 11: 1245–9.
43.
BotsM.L., HoesA.W., KoudstraalP.J.Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study.Circulation1997; 96: 1432–7.
44.
ChamblessL.E., HeisG., FolsomA.R.Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerotic Risk in Communities (ARIC) Study, 1987–1993.Am J Epidemiol1997; 146: 483–94.
45.
HodisH.N., MackW.J., LaBreeL.The role of carotid arterial intima media thickness in predicting clinical coronary events.Ann Intern Med1998; 128: 262–9.
46.
O'LearyD.H., PolakJ.F., KronmalR.A.Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults.N Engl J Med1999; 340: 14–22.
47.
HodisH.N., MackW.L., LabreeL.Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. A randomized, controlled clinical trial.Ann Intern Med1996; 124: 548–56.
48.
KroonA.A., Van AstenW.N.J.C., StalenhoefA.F.H.Effects of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.Ann Intern Med1996; 125: 945–54.
49.
BlankenhomD.H., SelzerR.H., CrawfordD.W.Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.Circulation1993; 88: 20–8.
50.
FurbergC.D., AdamsH.P., ApplegateW.B.for the Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events.Circulation1994; 90: 1679–87.
51.
TaylorA.J., KentS.M., FlahertyP.J.ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.Circulation2002; 106: 2055–60.
52.
Skoglund-AnderssonC., TangR., BondG.LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men.Arterioscler Thromb Vasc Biol1999; 19: 2422–30.
53.
De Sauvage NoltingP.R.W., TwicklerM.B., Dalling-ThieG.M.Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.Circulation2002; 106: 788–92.
